ABVC BioPharma Executes A Global Licensing Definitive Agreement For The Treatment Of NSCLC, Expecting Aggregate Income Of $13.75M And Royalties Of Up To $12.50M
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.